ストックスクリーナーアプリを入手
0.4622
12.54%
-0.0663
アフターアワーズ：
.45
-0.0122
-2.64%
前日終値:
$0.5285
開ける：
$0.4715
24時間の取引高:
2.58M
Relative Volume:
0.39
時価総額：
$321.81K
収益：
-
当期純損益:
$-14.93M
株価収益率:
-0.00174
EPS:
-266.137
ネットキャッシュフロー:
$-15.87M
1週間 パフォーマンス:
-11.12%
1か月 パフォーマンス:
-75.93%
6か月 パフォーマンス:
-97.72%
1年 パフォーマンス:
-97.85%
1日の値動き範囲:
$0.46
$0.52
1週間の範囲:
$0.4263
$0.67
52週間の値動き範囲:
$0.4263
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
RNAZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
0.4622 | 321.81K | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc (RNAZ) 最新ニュース
TransCode Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com
TransCode Therapeutics Delays Annual Report Filing - TipRanks
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Monday - Defense World
Emerging Tech QuartetPRSO, LXRX, PRTG, RNAZDrive - openPR.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN
(RNAZ) Investment Analysis - news.stocktradersdaily.com
Small Cap Stocks To Follow TodayMarch 23rd - MarketBeat
TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138 - MarketScreener
TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial - Marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cancer Drug Trial Hits Major Milestone: Zero Toxicity as Doses Increase 50% - Stock Titan
TransCode's $10M Capital Raise Powers Critical Cancer Drug Clinical Trials - Stock Titan
Transcode Therapeutics stock hits 52-week low at $0.64 By Investing.com - Investing.com Australia
TransCode Therapeutics Announces $10M Stock And Warrant Offering - Nasdaq
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Transcode Therapeutics stock hits 52-week low at $0.64 - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Transcode to sell 10.25M shares at 98c per share in registered direct offering - TipRanks
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics Starts $10 Million Direct Offering of Stock, Warrants -March 24, 2025 at 03:42 am EDT - Marketscreener.com
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - Stock Titan
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire
Small Cap Stocks To ResearchMarch 21st - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
(RNAZ) Long Term Investment Analysis - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ) - Defense World
RNAZ stock touches 52-week low at $0.69 amid sharp annual decline - Investing.com Canada
Biotech Alert: Searches spiking for these stocks today - TipRanks
SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138 - Yahoo Finance
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy - Nasdaq
Transcode Therapeutics’ fourth cohort in Phase 1/2 cancer trial approved - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers - Marketscreener.com
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial - Longview News-Journal
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care - Cancer Network
Transcode Therapeutics stock hits 52-week low at $1.7 By Investing.com - Investing.com Canada
Transcode Therapeutics stock hits 52-week low at $1.7 - Investing.com
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
The Significance of Moving Averages in TransCode Therapeutics Inc Inc. (RNAZ) Price Performance - The InvestChronicle
Transcode Therapeutics stock hits 52-week low at $2.62 By Investing.com - Investing.com South Africa
Transcode Therapeutics stock hits 52-week low at $2.62 - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com UK
TransCode Therapeutics, Inc. Announces Results of Special Meeting - Yahoo Finance
Transcode Therapeutics Inc (RNAZ) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):